BOSNIA AND HERZEGOVINA


CERVICAL CANCER PROFILE

TOTAL POPULATION. FEMALE (2019): 1 684 000

TOTAL DEATHS. FEMALE (2019): 18 600


Morbidity and Mortality

Crude cervical cancer incidence per 100 000 women (2020):	18.6
Age-standardized cervical cancer incidence	
per 100 000 women (2020):	14.3
Cumulative risk of cervical cancer, ages 0-74 (2020):	1.3%
Cervical cancer deaths (2019):	130
Cervical cancer mortality-to-incidence ratio (2020):	0.49
Population-based cancer registry exists (2021):	Yes



Primary Prevention

HPV vaccination programme coverage among girls (2020)



HPV vaccination is not included in the national vaccination schedule


HPV vaccination programme (2020):

No
-
-
-


Related risk factors:

Tobacco use prevalence, women aged 15+ years (2020)**:	28%
Condom use at last high-risk sex (-):	ND
HIV incidence per 1000, women aged 15+ years (2020):	ND

Secondary Prevention



Screening for cervical cancer (2019)



2 in 10 women have been screened for cervical cancer in the last 5 years

Treatment and Supportive Care

National guidelines on cervical cancer management	
exist (2021):	No

Number of radiotherapy units per 10 000 cancer patients (2021):	8
Number of brachytherapy units per 10 000 cancer patients (2021):	2

Cancer diagnosis and treatment services generally available (2021):

Cancer centre or cancer department at tertiary level:	Yes
Pathology services (laboratories):	Yes
Cancer surgery:	Yes
Chemotherapy:	Yes
Radiotherapy:	Yes

Number of medical staff (per 10 000 cancer patients):

Radiation oncologists (2019):	ND
Medical physicists (2019):	12
Surgeons (2013):	191
Radiologists (2019):	131
Nuclear medicine physicians (2019):	19

Palliative care for patients with NCDs in the public health system generally available (2021):

In primary health care facilities:	No
In community or home-based care:	No

Reported annual opioid consumption excluding methadone - in oral morphine equivalence per capita (2017):

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15

70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age

90% of women identified with cervical disease receive treatment

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls) † Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any

time between ages 9 to 14

**Data refer to tobacco smoking only, in absence of sufficient data on all tobacco use